Replies to post #243807 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Umibe5690,

This post is out of sync but I wanted you to look at table 4 in the Carlos Rago report. See post 243810 for the link. Tumor mutational burden is high in unmethylated MGMT status patients and that correlates to a large extent with mesenchymal. More targets for the vaccine to hit. Older patients also tend to have lowered Treg counts which are known to interfere with T cells activated by the vaccine. When you look at the table there is plenty of evidence to show how the vaccine might grant advantages in certain situations. Best wishes.